SCHEMBL18558287

SCHEMBL18558287

Cc1cc(N/C(=N\C(=O)c2ccc(F)c(F)c2)NCCC(F)(F)F)[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.35
KCNQ2 O43526 3/20 0.35
GSK3B P49841 2/20 0.35
DYRK1A Q13627 2/20 0.35
MAPT P10636 3/20 0.34
TP53 P04637 2/20 0.34
TRPA1 O75762 1/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34
LMNA P02545 1/20 0.34
KCNJ6 P48051 1/20 0.33
KCNJ5 P48544 1/20 0.33
KCNJ3 P48549 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
HTRA1 Q92743 1/20 0.33
KCNQ5 Q9NR82 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
NPC1 O15118 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18558602 0.92 HDAC6 (0.36) KCNQ3KCNQ2GSK3BDYRK1AABL1
SCHEMBL18558427 0.87 KCNQ3 (0.35) KCNQ3KCNQ2MAPTTP53TRPA1
SCHEMBL18558165 0.87 HDAC6 (0.37) GSK3BDYRK1AMAPTABL1BCR
SCHEMBL18558606 0.85 LMNA (0.40) KCNQ3KCNQ2DYRK1AABL1BCR
SCHEMBL18558432 0.83 CHRNA1 (0.38) KCNQ3KCNQ2CES2CES1KCNQ5
SCHEMBL17088577 0.80 P2RX7 (0.46)
SCHEMBL9921075 0.79 MAPT (0.34) KCNQ3KCNQ2MAPTTP53TRPA1
SCHEMBL18558166 0.78 NPC1 (0.41) KCNQ3KCNQ2DYRK1ANPC1RAB9A
SCHEMBL9920876 0.77 LMNA (0.33) KCNQ3KCNQ2MAPTTP53TRPA1
SCHEMBL18558358 0.76 HDAC6 (0.38) KCNQ3KCNQ2KCNQ5POLBKCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932313-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-04-03 US disclosed
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-09-21 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME KCNQ3 2176/4885KCNQ2 1839/4885GSK3B 4597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.